ANGIO2013

The 15th International Symposium on Anti-Angiogenic Therapy:Recent Advances and Future Directions in Basic and Clinical Cancer Research

January 31–February 2, 2013

Hyatt Regency La Jolla • 3777 La Jolla Village Drive • San Diego, California

www.antiangio2013.comFor Information and Poster Submission Form

EvaluationA course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improve-ment activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

Accreditation/Credit DesignationThe University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 14.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Certificates and Attendance Verification CertificatesCertificates awarding AMA PRA Category 1 CreditTM or certificates documenting attendance will be distributed to participants when an individual departs the conference. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a CME Verification Form.

Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

POSTER SUBMISSION/ SESSION:The symposium will feature a poster session where academics and investigators from the industry present angiogenesis-related data from both clinical trials and laboratory research. Trainees are especially encouraged to present their research. Accepted posters will be displayed with ample time for viewing and discussions

All symposium participants, including members of industry, are encouraged to present research data as part of the poster session.

The deadline for submitting poster applications is Friday, December 14, 2012.

Please check the website for more information and the submission form at www.antiangio2013.com.

Program OverviewAngiogenesis is an essential process in the growth of neoplasms and progression to metastasis. The angiogenic pathway is orchestrated by a range of pro- and anti-angiogenic factors that ultimately lead to the development of a neovascular blood supply to the tumor mass. Vascular endothelial growth factor (VEGF), which stimulates proliferation and migration of endothelial cells, plays a pivotal role in this process. For these reasons, the inhibition of VEGF and its receptor signaling system are attractive targets for therapeutic intervention. Indeed, the approval in 2004 of a neutralizing monoclonal antibody directed against VEGF – the first anti-angiogenic systemic drug to treat cancer patients-validated the notion introduced decades earlier that inhibition of tumor angiogenesis may be a valid approach to control tumor growth. This success has driven the search for new anti-angiogenic agents. For example, small-molecule multikinase inhibitors that target VEGF receptors have recently demon-strated efficacy in multiple tumor types. A number of other anti-angiogenic agents targeting an increasing variety of molecular tumor features are in clinical development. More recently, studies of powerful new genetic and cell biological approaches have provided unprecedented insights into how various molecular are pivotal to tumor growth and survival. As a consequence, a number of new angiogenic molecules, such as neuropilins, Tie-2, and Notch ligand delta-like 4, have emerged as promising targets.

Since its inception over 4 decades ago, investigators in the field of tumor angiogenesis research have made significant progress. Advancements in therapeutics have altered cancer treatment paradigms, and the next decade promises to be an exciting and productive time. This annual state-of-the-art symposium is designed to continue the dialogue and interaction between research and clinical investigators by reviewing the current scientific understanding of vascular biology and angiogenesis. In addition, this symposium provides a forum for presenting the most current preclinical and clinical data on emerging anti-angiogenic agents and regimens. Strategies that inhibit angiogenesis in colorectal, breast, lung, esophageal, gastric, genitourinary, neuroendocrine, central nervous system, hepatocellular and gynecologic malignancies will be discussed. In addition, biomarkers and resistance pathways will be addressed and controversies in the field will be highlighted.

Educational ObjectivesAfter attending the symposium, participants should be able to• Defineangiogenesisanditsrelevancetothetreatmentofcancer(Knowledge);• Outlinetherationaleforthedevelopmentofanti-angiogeneicagents,andexplainwhy

angiogenic signaling pathways are targets for inhibition (Knowledge);• Summarizedatafromclinicaltrialsthatsupporttheuseofcurrentlyavailableanti-angiogenic

agents as monotherapy or in combination with other therapeutic modalities, which will ultimately assist the healthcare provider to make appropriate clinical decisions (Knowledge, Competence, Performance, Patient Outcomes);

Target AudienceThis symposium is designed for medical, surgical, and radiation oncologists, pharmacists, other providers of cancer care (PAs, RNs, etc.), and research scientists who have an interest in the biology, diagnosis, and treatment of cancer, as well as those who diagnose and treat patients with nonmalignant vascular diseases, such as arthritis and retinal neovascularization. As new and emerging data on anti-angiogenic therapy is presented at this symposium every year, it is necessary for this audience to be made aware of these findings so they can be utilized in their clinical practice.

Educational MethodsLectures–PanelDiscussions–QuestionandAnswer–PosterSession

Lee M. Ellis, MDProfessor of Surgery and Cancer BiologyWilliam C. Liedtke, Jr., Chair in Cancer ResearchThe University of Texas MD Anderson Cancer CenterHouston, Texas

Robert S. Kerbel, PhDCanada Research Chair in Tumor Biology, Angiogenesis and Anti-Angiogenic TherapyUniversity of TorontoProfessor, Molecular and CellularBiology ResearchSunnybrook Health Sciences Centre/Odette Cancer CentreToronto, Ontario, Canada

George W. Sledge, Jr., MDBallve-Lantero Professor of OncologyCo-Director, Breast Cancer ProgramIndiana University Melvin and Ben Simon Cancer CenterIndianapolis, Indiana

Helen X. Chen, MDSenior Investigator in Cancer TherapyEvaluation ProgramNational Cancer InstituteRockville, Maryland

Axel Grothey, MDProfessor of OncologyDivision of Medical OncologyMayo Clinic Division of Medical OncologyRochester, Minnesota

Planning Committee

Wednesday, January 30, 20133:00–7:00 p.m. Registration

Thursday, January 31, 20137:30–8:00 a.m. Registration/Continental Breakfast

Session I: Basic Biology and Preclinical Data Moderator:LeeM.Ellis,MD;RobertS.Kerbel,PhD

8:00–8:30 Opening Remarks/Overview LeeM.Ellis,MD 8:30–8:55 Combinatorial Targeting of Endothelial Growth Factors and Receptors KariAlitalo,MD,PhD 8:55–9:20 Tumor Hypoxia: Is Targeting HIF a Viable Approach? M.CelesteSimon,PhD 9:20–9:45 Metronomic Chemotherapy with Anti-Angiogenic Drugs:

An Update RobertS.Kerbel,PhD 9:45–10:10 Resistance to VEGF-Targeted Therapies TBD

10:10–10:30 Break 10:30–10:55 Anti-Angiogenic Agents Stimulate Breast Cancer

Stem Cells via Generation of Tumor Hypoxia MaxS.Wicha,MD 10:55–11:10 Abstract #1 11:10–11:35 The Role of SDF-1/CXCR4 Signaling in Angiogenesis MartinBrown,DPhil 11:35–Noon Oscillation of Immune Cells in Response to

Anti-Angiogenic Therapy GabrieleBergers,PhD Noon–1:00 p.m. Lunch

Program Session II: Biomarkers and ImagingModerator:RobertS.Kerbel,PhD

1:00–1:25 Predictive Biomarkers: VEGF Amplifications and Host Polymorphisms

BryanP.Schneider,MD1:25–1:50 Predictive Biomarkers: Imaging and Circulating VEGF GordonJayson,MD,PhD1:50–2:05 Abstract #22:05–2:30 Standardizing Imaging Criteria to Assess the Effect of Anti VEGF Therapy in Brain Tumors BradleyJ.Erickson,MD,PhD2:30–2:55 The FDA Pre-IDE Process:

Lessons Learned for Integral Markers J.MilburnJessup,MD2:55–3:15 Break3:15–3:45 Panel Discussion: Implementation of Biomarkers Moderator:LeeM.Ellis,MD Panelists:S.GailEckhardt,MD;BradleyJ.Erickson,MD,PhD;

AxelGrothey,MD;GordonJayson,MD,PhD; J.MilburnJessup,MD;BryanP.Schneider,MD

3:45–5:30 p.m. Poster Reception

Friday, February 1, 20137:30–8:00 a.m. Registration/Continental Breakfast

Session III: Controversies and New HorizonsModerators:AxelGrothey,MD;GeorgeW.Sledge,Jr.,MD

8:00–8:05 Introduction GeorgeW.Sledge,Jr.,MD

8:05–8:25 Is RECIST Still Relevant in the Era of VEGF Inhibition Through Multiples Lines of Therapy?

Implications for Clinical Trial Design in All Malignancies AxelGrothey,MD

8:25– 8:50 Patient Derived Xenograft Models: Are They Appropriate For Anti-Angiogenic and Microenvironment Therapies? S.GailEckhardt,MD

8:50–9:15 From the Laboratory to the Labrador: Spontaneous Canine Cancer as a Model for Anti-Angiogenic Drug Development DouglasH.Thamm,VMC,DACVIM

9:15–9:40 Promise and Pitfalls of Anti-Angiogenic Therapy in the Adjuvant Setting

DanielF.Hayes,MD

9:40–10:00 Break

Session IV: Early Drug DevelopmentModerators:HelenX.Chen,MD;GeorgeW.Sledge,Jr.,MD

10:00–10:15 Early Drug – Phase I MichaelS.Gordon,MD

10:15–10:30 Early Drug – Phase I LeeS.Rosen,MD

10:30–10:45 Abstract #3

10:45–11:00 A Phase I Clinical Trial of VX15/2503, A Novel Humanized IgG4 Anti-SEMA4D Antibody, In Patients With Advanced Solid Tumors

AmitaPatnaik,MD

11:00–11:25 The Role of CTEP in the Development of Angiogenesis Inhibitors

HelenX.Chen,MD

11:30–12:30 p.m. Lunch

Session V: Clinical Trial ResultsModerator:HelenX.Chen,MD;MichaelS.Gordon,MD

12:30-12:55 Anti-Angiogenic Therapy for the Treatment of Hepatocellular Carcinoma

GhassanK.Abou-Alfa,MD

12:55–1:20 Anti-Angiogenic Therapy for the Treatment of Sarcoma GaryK.Schwartz,MD

1:20–1:45 Anti-Angiogenic Therapy for the Treatment of Ovarian Cancer GordonJayson,MD,PhD

1:45–2:05 Break

2:05–2:30 Anti-Angiogenic Therapy for the Treatment of Colorectal Cancer

CharlesD.Blanke,MD

2:30–2:45 Abstract #4

2:45–3:10 Anti-Angiogenic Therapy for the Treatment of Renal Cell Carcinoma

EricJonasch,MD

3:10–3:35 Vascular Disrupting Agents GordonRustin,MD

3:35 Adjourn

Saturday, February 2, 2013 7:30–8:00 a.m. Registration/Continental Breakfast

Session V: Clinical Trial Results Moderator:AxelGrothey,MD

8:00–8:05 Introduction AxelGrothey,MD

8:05–8:30 Clinical Overview and Perspectives on Anti-Angiogenic Therapy in CNS Tumors

PatrickY.Wen,MD

8:30–8:55 Antio-Angiogenic Therapy for the Treatment of Neuroendocrine Tumors

JamesC.Yao,MD

8:55–9:10 Abstract #5 9:10–9:35 Anti-Angiogenic Therapy for the Treatment of Lung Cancer CoreyJ.Langer,MD

9:35–10:00 Anti-Angiogenic Therapy for the Treatment of Breast Cancer GeorgeW.Sledge,Jr.,MD

10:00 Closing Remarks

10:15 Adjourn

Registration InformationOn-site registration will be open from 3:00-7:00 p.m. on Wednesday, January 30, 2013, and at 7:30 a.m. on Thursday, January 31. The conference will begin at 8:00 a.m. on Thursday, January 31, and adjourn at 10:15 a.m. on Saturday, February 2. Advance registration is encouraged as space and materials are limited. Please see registration form for applicable fees.

The deadline for advance registration is January 16, 2013.

There are three ways to register:• Mailto:CME/ConferenceManagement–Unit1381,TheUniversityofTexas

MD Anderson Cancer Center, P.O. Box 301439, Houston, TX 77230-1439• Faxto:713-794-1724• On-lineatwww.mdanderson.org/conferences

We accept the following forms of payment:• Check(payablethroughU.S.banksonly)• MoneyOrder• CreditCards(MasterCard,VISA,andAmericanExpress)• Cash(on-siteregistrationonly)

A receipt and confirmation letter will be sent to you within ten working days of receipt of your fee.

The full conference registration fee includes the tuition, breaks, lunch, and poster reception.

Refund/Cancellation Policy: The registration fee, minus a $50 administrative handling fee, is refundable if a written request is received on or before January 16, 2013. No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check.

TheDepartmentofCME/ConferenceManagementreservestherighttocancelactivities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or the contact numbers as given on the registration form.

Incaseofactivitycancellation,liabilityoftheDepartmentofCME/ConferenceManagement is limited to the registration fee. CME/Conference Management will refund the full registrationfee.TheDepartmentofCME/ConferenceManagementreservestherighttolimitthe number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available.

For additional information, contact CME/Conference Management at 713-792-2223 or toll free at 866-849-5866.

Ghassan K. Abou-Alfa, MDAssociate Attending ProfessorMemorialSloan-Kettering Cancer CenterNew York, New York

Kari Alitalo, MD, PhDResearch Professor of the Academy of FinlandBiomedicumHelsinkiUniversityofHelsinkiHelsinki,Finland

Gabriele Bergers, PhDProfessor Brain Tumor Research CenterUniversity of CaliforniaSan FranciscoSan Francisco, California

Charles D. Blanke, MDVice-PresidentSystemic TherapyBritish Columbia Cancer AgencyProfessor&Chief,MedicalOncologyUniversity of British ColumbiaVancouver, British ColumbiaCanada

Martin Brown, DPhilProfessorStanford UniversityDivisionofRadiationand Cancer BiologyPalo Alto, California

Helen X. Chen, MDSenior Investigator in Cancer TherapyEvaluation ProgramNational Cancer InstituteRockville, Maryland

S. Gail Eckhardt, MDProfessorandDivisionHeadMedicalOncologyStappHarlowChairin Cancer ResearchUniversityofColoradoDenverAurora, Colorado

Lee M. Ellis, MDProfessor of Surgery and Cancer BiologyWilliam C. Liedtke, Jr. Chair in Cancer ResearchThe University of Texas MDAndersonCancerCenterHouston,Texas

Bradley J. Erickson, MD, PhDAssociate Professor of Radiology and InformaticsMayo Medical SchoolMayo ClinicRochester, Minnesota

Michael S. Gordon, MDMedicalOncologyPinnacleOncologyHematologyScottsdale, Arizona

Axel Grothey, MDProfessorofOncologyMayo Clinic College of MedicineRochester, Minnesota

Daniel F. Hayes, MDClinicalDirectorBreastMedicalOncologyProgramStuart B. Padnos Professor in Breast CancerUniversity of Michigan Comprehensive Cancer CenterAnn Arbor, Michigan

Gordon Jayson, MD, PhDProfessorofMedicalOncologyThe University of ManchesterWithington, ManchesterUnitedKingdom

J. Milburn Jessup, MDChief,Diagnostics Evaluation BranchCancerDiagnosisProgramNational Cancer InstituteRockville, Maryland

Eric Jonasch, MDAssociate Professor ofGenitourinaryMedicalOncologyTheUniversityofTexasMDAnderson Cancer CenterHouston,Texas

Robert S. Kerbel, PhDCanada Research Chair in Tumor Biology, Angiogenesis and Anti-Angiogenic TherapyUniversity of TorontoProfessor, Molecular and Cellular Biology ResearchSunnybrookHealthSciences Center/OdetteCancerCenterToronto,Ontario,Canada

Corey J. Langer, MDProfessor of MedicineUniversity of PennsylvaniaPerelman Center for Advanced MedicinePhiladelphia, Pennsylvania

Amita Patnaik, MDAssociateDirectorof Clinical ReserarchSTARTSan Antonio, Texas

Lee S. Rosen, MDProfessor of Clinical MedicineDivisionofHematology-OncologyUniversity of CaliforniaLos Angeles, California

Gordon Rustin, MDDirectorofMedicalOncologyMount Vernon Cancer CentreNorthwood, MiddlesexUnitedKingdom

Bryan P. Schneider, MDAssociate ProfessorIndiana University Melvin and Bren Simon Cancer CenterIndianapolis, Indiana

Gary K. Schwartz, MDChiefMelanoma and Sarcoma ServiceAttending PhysicianMemorialSloan-Kettering Cancer CenterNew York, New York

M. Celeste Simon, PhDProfessor of Cell and DevelopmentalBiologyUniversity of PennsylvaniaHowardHughesMedicalInstitutePhiladelphia, Pennsylvania

George W. Sledge, Jr., MDBallve-LanteroProfessorofOncologyCo-Director,BreastCancerProgramIndiana University Melvin and Bren Simon Cancer CenterIndianapolis, Indiana

Douglas H. Thamm, VMC, DACVIMAssistant Professor andBarbara Cox Anthony Chair inOncologyDirectorofClinicalResearchThe Animal Cancer CenterColorado State University Cancer CenterFort Collins, Colorado

Patrick Y. Wen, MDProfessor of NeurologyHarvardMedicalSchoolDirector,CenterforNeuro-OncologyDanaFarberCancerInstituteBoston, Massachusetts

Max S. Wicha, MDProfessorDepartmentofInternalMedicineDirectorUniversity of MichiganComprehensive Cancer CenterAnn Arbor, Michigan

James C. Yao, MDAssociate ProfessorGIMedicalOncologyThe University of Texas MDAndersonCancerCenterHouston,Texas

Faculty

CO

NFE

RE

NC

E R

EG

IST

RA

TIO

N -

059

7

The 1

5th I

nterna

tiona

l Sym

posiu

m on

Anti

-Ang

iogen

ic Th

erapy

: Re

cent

Adva

nces

and F

uture

Direc

tions

in Ba

sic an

d Clin

ical C

ance

r Res

earch

, Jan

uary

31–

Febru

ary 2,

2013

THIS

IS N

OT A

SEL

F-M

AILE

R

ADDR

ESS

TO:

The 1

5th In

terna

tiona

l Sym

posiu

m on

Anti

-Ang

iogen

ic Th

erapy

: Re

cent

Adva

nces

and F

uture

Direc

tions

in B

asic

and C

linica

l Can

cer R

esea

rch

Depa

rtmen

t of C

ME/

Conf

eren

ce M

anag

emen

t–Un

it 13

81Th

e Un

iver

sity

of T

exas

MD

Ande

rson

Can

cer C

ente

rPO

Box

301

439,

Hou

ston

, TX

7723

0-14

39

or fa

x to

713

-794

-172

4

Mak

e ch

eck

or m

oney

ord

er p

ayab

le to

:Th

e Un

iver

sity

of T

exas

MD

Ande

rson

Can

cer C

ente

r

REG

ISTR

ATI

ON

FEE

S1

Pos

tmar

ked

by 1/

16/1

3 .....

.......

$ 275

.001

Pos

tmar

ked

afte

r 1/1

6/13

........

$ 325

.00

Trai

nees

: 1

Pos

tmar

ked

by 1/

16/1

3 .....

......$

100.0

0 1

Pos

tmar

ked

afte

r 1/1

6/13

.......

$ 150

.00 1

Tra

inee

Sub

mitt

ing

Post

er ...

.$

50.00

Depa

rtmen

t Cha

ir sh

ould

verif

y Tra

inee

stat

us

by si

gnin

g be

low

:

____

____

____

____

____

____

____

____

___

Regi

stra

tion

also

ava

ilabl

e on

-lin

ew

ww

.ant

iang

io20

13.c

om

Special AssistanceContact the Department of CME/Conference Management at 713-792-2223 or toll free at 866-849-5866 if you have any special dietary or ADA accommodation needs.

Accommodations• Ablockofroomshasbeenreservedforconferenceattendeesatthe

Hyatt Regency La Jolla,3777LaJollaVillageDrive,SanDiego,California.• Earlyhotelreservationissuggested.• Thehotelreservationsnumberis858-552-1234.• WhenyoumakereservationsbesuretomentiontheMD Anderson 15th

International Symposium on Anti-Angiogenic Agents to be assured of receiving the special meeting rate of $215.00 single or double occupancy. Please add 12.5% California state and local taxes. Reservations and deposits received after December 28, 2012 will be confirmed if space is available and at current hotel published guest room rates.

Ground TransportationThe hotel is approximately 20 miles from the San Diego International Airport. Taxi rates are approximately $45 one way.

TheUniversityofTexasMDAndersonCancerCenterhasimplementedaprocesswherebyeveryonewhoisin a position to control the content of an educational activity must disclose all relevant financial relationships withanycommercialinterestthatcouldpotentiallyaffecttheinformationpresented.MDAndersonalsorequires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience.MDAndersonmaysubstitutefacultywithcomparableexpertiseonrareoccasionsnecessitatedby illness, scheduling conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chairs for consideration. La

st N

ame

Firs

t

MI

Hig

hest

Deg

ree

Depa

rtmen

t (in

clud

e bo

x no

.)

Spe

cial

ty

Inst

itutio

n

Stre

et

City

Sta

te/F

orei

gn C

ount

ry/Z

ip o

r Mai

l Cod

e

Dayt

ime

Phon

e (w

ith a

rea

code

)

Ce

ll Ph

one

(with

are

a co

de)

Fax

(with

are

a co

de)

E-m

ail A

ddre

ss

E

mer

genc

y Co

ntac

t

P

hone

(with

are

a co

de)

Char

ge th

e fo

llow

ing:

o

VISA

o

Mas

terC

ard

oAm

eric

an E

xpre

ss

Cred

it Ca

rd N

umbe

r or M

D An

ders

on In

terd

epar

tmen

tal T

rans

fer (

IDT)

No.

Expi

ratio

n Da

te

Cred

it Ca

rd H

olde

r Nam

e (F

irst/L

ast)

C

redi

t Car

d Ho

lder

Bill

ing

Addr

ess

& Z

IP C

ode

Auth

orize

d Si

gnat

ure

REQU

IRED

for c

redi

t car

d or

IDT

MD

Ande

rson

Em

ploy

ee ID

No.

(REQ

UIRE

D)

IDT

Appr

over

Nam

e (F

irst/L

ast)

plea

se p

rint

IDT

Appr

over

E-m

ail

Phys

icia

n

oYe

s o

No

Departm

entofCME/ConferenceManagem

ent-Unit1381

TheUniversityofTexasMDAndersonCancerCenter

# 17

6700

/110

501

POBox301439

Houston,TX77230-1439

Non

-Pro

fit O

rg.

U.S

. Pos

tage

P A

I D

Hou

ston

, TX

Per

mit

No.

705

2